Evaluating the efficacy of neoadjuvant endocrine therapy in HER2 low vs. HER2 negative breast cancer: An NCBD analysis

被引：0
|
作者：
Chong, Esther G.
Guo, Mengni
Castillo, Dani Ran
Bazan, Jose G.
Yap, Kelly Khai Li
Schultz-Costello, Katharine
Wu, S. Peter
机构：
[1] Loma Linda Univ, Dept Oncol Hematol, Med Ctr, Loma Linda, CA USA
[2] City Hope Natl Canc Ctr, Duarte, CA USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
599
引用
收藏
页数：1
相关论文
共 50 条
  • [21] HER2 up-regulation with neoadjuvant endocrine therapy in patients with hormone receptor-positive, HER2-negative breast cancer
    Chaudhary, Lubna N.
    Jorns, Julie
    Gonyo, MaryBeth
    Kong, Amanda
    Peck, Amy R.
    Sun, Yunguang
    Bergom, Carmen
    Banarjee, Anjishnu
    Chitambar, Christopher
    Rui, Hallgeir
    CANCER RESEARCH, 2020, 80 (04)
  • [22] Her2 FISH amplification in ER/PR/Her2 IHC negative breast cancer
    Sahoo, Sunati
    Hwang, Helena
    CANCER RESEARCH, 2015, 75
  • [23] HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX
    Tozbikian, Gary H.
    Zynger, Debra L.
    BREAST JOURNAL, 2018, 24 (04): : 535 - 540
  • [24] Clinical and pathological characteristics of HR plus breast cancer with HER2 low and HER2(0) expression: exploring endocrine therapy sensitivity
    Jin, Xin
    Ma, Yun-Fei
    Sun, Tong-Jun
    Xie, Qiang
    Yin, Fa-Xiang
    Zhang, Li-Gong
    Zhao, Yan
    Zhao, Yan
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (12) : 6850 - 6861
  • [25] Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
    Porte, B.
    Carton, M.
    Lerebours, F.
    Brain, E.
    Loirat, D.
    Haroun, L.
    Bellesoeur, A.
    Hamba, S. Bach
    Kirova, Y.
    Cottu, P.
    BREAST, 2020, 54 : 303 - 310
  • [26] Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
    Porte, Baptiste
    Carton, Matthieu
    Loirat, Delphine
    Bidard, Francois-Clement
    Haroun, Linda
    Bellesoeur, Audrey
    Kirova, Youlia
    Cottu, Paul
    CANCER RESEARCH, 2021, 81 (04)
  • [27] Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer
    Fujita, Tetsuji
    LANCET, 2012, 379 (9833): : 2237 - 2237
  • [28] The association of higher tumor HER2 load with treatment response to neoadjuvant therapy in HER2 positive breast cancer patients
    Lillemoe, T. J.
    Susnik, B.
    Grimm, E.
    Kang, S-H L.
    Swenson, K. K.
    Krueger, J. L.
    Finkelstein, M. J.
    Tsai, M. L.
    CANCER RESEARCH, 2017, 77
  • [29] Survival analysis of HER2 receptor negative and HER2 receptor low breast cancer patients at a Philippine Tertiary Government Hospital
    Arenos, Carl
    Lim, Steven
    Lominoque, Andreu
    Reveldez, Isabela
    Sison-Dimaano, Angeli
    Pagandaman, Nehar
    Tatoy, Vincent
    Uy, Timothy
    San Juan, Michael
    ECANCERMEDICALSCIENCE, 2025, 19
  • [30] Reassessment of HER2 status in HER2 negative or HER2 unknown breast cancer patients with recurrent metastatic disease by analyzing serum HER2 and HER2 status of circulating tumor cells.
    Fehm, T.
    Lane, N.
    Solomayer, E.
    Wallwiener, D.
    Uhr, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S40 - S40
12345